An AI Drug Company Named a Candidate for Dry Macular Degeneration, and the Target Is Undisclosed
Source: Medical Daily· Elena Vega· August 7, 2026
Insilico Medicine nominated ISM9077 for dry AMD and other eye diseases. What a preclinical candidate designation means and what remains undisclosed.
This story was reported by Medical Daily. Read the full original article:
Read on Medical Daily 
